On April 20, 2026, the Common Package of Benefits of the Spanish National Health System was amended (by Order SND/356/2026, of April 13, 2026). The key changes relate to diagnostic imaging, in-vitro diagnostics, obstetrics and gynecology, and some other fields.

The French National Authority for Health (HAS) released new recommendations on the registration of medical devices and medical aids in the List of Reimbursable Products and Services (LPPR) following the April 2026 meetings of the National Commission for the Evaluation of Medical Devices and Health Technologies (CNEDiMTS). Favorable opinions were issued for the add-on reimbursement of 14 new devices and for the extension of indications for three devices. Opinions concerned multiple fields, including cardiovascular, diagnostic imaging, ENT, e-health, endocrine, interventional radiology, nephrology, neuromodulation, orthopedics, spine, peripheral vascular, and pulmonology.

In April 2026, the Danish Healthcare Quality Institute (DHQI) released its first Method and Process Guide for Health Technology Assessment (HTA). The guide outlines both the methodological framework for HTA and the overall process, covering topic selection, assessment, and the DHQI Council's recommendations to regions on the implementation of treatment methods (e.g., medical technologies and procedures).

Our goal at MTRC is to inform the decision-making of our clients and to support their market access activities. Below is a snapshot of our planned activities for the next two weeks. This can help our existing and prospective clients understand the potential scope of our support better. From the week of May 04th, we plan to work on 14 projects. Review the complete list of planned activities in this post.

In March-April 2026, Health Technology Wales (HTW) accomplished two full appraisals on salvage high-dose-rate brachytherapy for prostate cancer and AI-assisted ultrasound for the detection of deep vein thrombosis. Additionally, two Med Tech-related Topic Exploration Reports were published in the E-health and Pulmonology fields.

As of April 2026, the Dutch Healthcare Institute (ZIN) is working on coverage positions in several areas, including otorhinolaryngology, dentistry, vascular interventional radiology, and gastroenterology fields.

On April 17, 2026, the Innovation Committee of the Federal Joint Committee (G-BA) announced the opening of the application period for proposed topics for upcoming funding announcements in the areas of healthcare services research and new forms of care.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its EU HTA Publications Digest. In a recent publication, Taylor et al. explored challenges and opportunities associated with incorporating real-world evidence into submissions under the EU’s new Joint Clinical Assessment process.

On March 31, 2026, NHS England released an updated work plan for the development of Clinical Commissioning Policies for specialised services. The update includes three new MedTech-related policies in the cardiovascular and radiotherapy areas, as well as the initiation of a revision to the existing policy on TAVI. No policies have been published since the previous update. The status of ongoing policies has been revised.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Publications Digest. In a recent publication, Prakash et al. conducted a scoping review and modified Delphi consensus study to map and harmonize definitions of digital health-related terms for use in health technology assessment.

At the end of March, the entity managing the DRG system in Switzerland, SwissDRG, established several unscheduled add-on reimbursement categories (ZE) for the treatment of burns with skin substitutes (autogeneic, allogeneic, alloplastic, xenogeneic). These ZE categories are valid from January 1, 2026, until December 31, 2026, for use in specific Swiss burn centers.

On April 16, 2026, the French Ministry of Health announced the inclusion of the first in vitro diagnostic medical device under the reformed RIHN 2.0, designed to support innovative diagnostics through temporary reimbursement while evidence is generated. The selected technology is VisioCyt Bladder, an AI-assisted digital urine cytology, indicated for monitoring recurrence in non-muscle-invasive bladder cancer. This marks a key milestone in the implementation of the updated framework.